HARBOUR BIOMED
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.
HARBOUR BIOMED
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.harbourbiomed.com
Total Employee:
51+
Status:
Active
Contact:
+86-21-51370990
Email Addresses:
[email protected]
Total Funding:
312.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Mobile Non Scaleable Content Nginx Euro Microsoft Azure DNS PHP
Similar Organizations
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
I-Mab Biopharma
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
IASO Biotherapeutics
IASO Biotherapeutics is a biopharmaceutical company focused on the development of cell therapies in the field of oncology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
Lianchuang Biomedicine
Lianchuang Bio is a pharmaceutical company that offers R&D, production, and marketing of advanced pharmaceutical intermediates.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-12-19 | Harbour Antibodies | Harbour Antibodies acquired by Harbour Biomed | N/A |
Investors List
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series C - Harbour Biomed
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series C - Harbour Biomed
Octagon Capital Partners
Octagon Capital Partners investment in Series C - Harbour Biomed
Country Garden
Country Garden investment in Series C - Harbour Biomed
OrbiMed
OrbiMed investment in Series C - Harbour Biomed
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series C - Harbour Biomed
SK Holdings
SK Holdings investment in Series B - Harbour Biomed
Zhejiang University
Zhejiang University investment in Series B - Harbour Biomed
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series B - Harbour Biomed
GIC
GIC investment in Series B - Harbour Biomed
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-14 | Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer |
| 2021-12-02 | Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer |
| 2021-07-20 | Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer |
Official Site Inspections
http://www.harbourbiomed.com Semrush global rank: 3.95 M Semrush visits lastest month: 3.16 K
Unable to get host informations!!!
More informations about "Harbour Biomed"
About Us - HBM Holdings - HARBOUR BIOMED
Dr. Xiaolu Tao is currently President of Harbour Therapeutics. She has more than ten years of experience in drug R&D in the United States, and has been responsible for the translational medicine and clinical pharmacology of …See details»
Corporate Governance - HBM Holdings - HARBOUR …
He has also been a member of the European Molecular Biology Organization since 1976. Xiaoping Ye Independent non-executive Director. Mr. Xiaoping Ye, Ph.D. (叶小平), in an independence non-executive Director of our Company. …See details»
HARBOUR BIOMED - LinkedIn
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on …See details»
Harbour Biomed - Crunchbase Company Profile
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms …See details»
和铂医药 | 专注于创新药研发及商业化的全球生物制药公司
和铂医药，一家专注于创新药研发、商业化及全球运营的生物制药企业，针对肿瘤及免疫性疾病领域创制具有巨大临床价值的生物新药。公司自有的Harbour Mice®平台能产生拥有全人源抗 …See details»
Harbour BioMed - Overview, News & Similar companies - ZoomInfo
Aug 8, 2023 Harbour BioMed has announced that Humphrey Gardner has joined the organization as Chief Medical Officer. Previously, Gardner served as Chief Medical Officer for …See details»
Harbour BioMed Company Profile 2024: Stock Performance
Harbour BioMed General Information Description. HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated …See details»
HARBOUR BIOMED | 领英 - 领英 (中国)
HARBOUR BIOMED | 在领英上有 3,949 位关注者。Healthy Life · Breakthrough Medicines | Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the …See details»
Harbour BioMed Acquires Harbour Antibodies to Create Global, …
Dec 19, 2016 CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands–(BUSINESS WIRE)–Harbour BioMed, a recently established Shanghai-based …See details»
Harbour BioMed - Craft
Harbour BioMed is a biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. Its discovery and development programs are …See details»
Harbour BioMed and The Wistar Institute Join Forces to Advance …
Www.harbourbiomed.com. The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the …See details»
Career - HBM Holdings - HARBOUR BIOMED
Multiple career path by Scientist/Manage channel, Internal Referral/transfer, organization upgradeSee details»
Harbour BioMed Completes Its Global Offering and Listing on the …
Dec 17, 2020 CAMBRIDGE, Mass. and SUZHOU, China, Dec. 16, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour BioMed", "HBM" or the "Company"; Stock Code: 02142.HK), a …See details»
Jingsong Wang – CEO, Harbour BioMed, China
Mar 4, 2019 Harbour BioMed is a global organization and as such, China plays a critical role in our overall strategy. China now offers a supporting regulatory landscape as well as an …See details»
Harbour BioMed to Present the Latest Progress of the First-in …
Jul 26, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody …See details»
Harbour BioMed Announces 2022 Interim Results: Revenue Grows …
Aug 31, 2022 CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2022 . Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical …See details»
Harbour BioMed and PPD Form Strategic Collaboration to Develop ...
Aug 27, 2019 PPD Contacts Media: Randy Buckwalter +1 919 456 4425 [email protected] Investors: Thomas Wilson +1 910 558 6423 …See details»
Harbour BioMed Raises $102.8M in Series C Financing to …
Jul 9, 2020 For more information, please visit www.harbourbiomed.com. About Hudson Bay Capital. Hudson Bay Capital (“HBC”) is a multi-billion-dollar asset management firm operating …See details»
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business …
Nov 14, 2024 Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 . Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical company committed to …See details»